OneSource Specialty Pharma LimitedNSE: ONESOURCE

Press Release May 04 2026

· Issued by OneSource Specialty Pharma Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

OneSource Specialty Pharma Limited has issued a press release regarding the approval of a second generic semaglutide in Canada, enabling commercialization for its partners in this significant market. The approval reflects a successful collaboration between OneSource and its partner Orbicular, showcasing OneSource's capabilities in manufacturing and supporting complex pharmaceutical products. CEO Neeraj Sharma emphasized the importance of these approvals for their global customers and the strength of their CDMO platform.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated May 04, 2026, titled "OneSource Supports Second Generic Semaglutide Approval in Canada-Enables commercialisation for the first two entrants in the world s second-largest semaglutide market".

OneSource Specialty Pharma Limited on 6ix

Earlier from OneSource Specialty Pharma

Later from OneSource Specialty Pharma

All OneSource Specialty Pharma news releases